Surgeon General Vivek Murthy Asked to Resign
On Friday, Surgeon General Vivek Murthy, MD, MBA, stepped down and was replaced by his deputy. Murthy, a holdover from the Obama administration, was asked to resign by the Trump administration, reported The New York Times. Rear Admiral Sylvia Trent-Adams, who served as Murthy’s deputy, is now the acting surgeon general. During his time as surgeon general, Murthy drew attention to gun violence, addressed the rising incidence in addiction to opioids and other substances, and also focused on improving disease prevention.
House Won’t Rush Healthcare Vote
While the White House had been pushing for a vote on a healthcare bill this week, right around President Donald Trump’s 100-day mark, House Speaker Paul Ryan, R-Wisconsin, indicated that wasn’t likely. According to Politico, Ryan is focusing on avoiding a government shutdown first and foremost and has not promised a new timeline for a vote on the amended healthcare bill. Lawmakers have just 4 days to pass a spending bill to avoid a government shutdown when funding expires on Friday.
Testing an Alzheimer’s Drug in Those Without Disease
Novartis is taking a different approach to testing its 2 new Alzheimer’s drugs. The company is testing the drugs in people who don’t have the disease but whose genes put them at high risk for developing it, according to The Wall Street Journal. So far no drugs have successfully delayed the progression of Alzheimer’s, so Novartis is hoping to treat early before the disease takes hold. However, recruiting participants is tough, because even though someone has a gene putting them at risk of Alzheimer’s doesn’t mean they’ll ever develop the disease.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More